Alpha Sense BI

APRIL 29, 2024

Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

MARCH 13, 2024

According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs. In January, HATCo announced its intent to acquire Summa Health of Ohio , a non-profit healthcare system, with a focus to “put innovation in.”

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59

Alpha Sense BI

MAY 5, 2023

Around the world, investors are favoring companies that have proven their profitability and that can demonstrate how they have successfully utilized their capital. M&A Trends by Industry Healthcare The COVID-19 pandemic ushered in a wave of unprecedented innovation, progress, and transformation to the healthcare industry in 2020.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

APRIL 19, 2024

2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion. On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. Over the past few years, the technology industry has experienced dramatic highs and lows.

Technology 69

Technology Technology Retail Biotech 69

Engage3

MAY 19, 2022

Ken served on the Board of Directors of Revionics between 2007-2011 and as Chief Scientist & VP of Innovations at SAP AG between 2006-2007. Tim Ouimet Founder & Board Observer Tim Ouimet is a Founder and Board Member at Engage3 and is a recognized industry innovator in retail pricing strategies.

Retail 52

Retail Capital Finance Biotech 52